efineptakin alfa

Home
Ligands
efineptakin alfa

GtoPdb Ligand ID: 11097

Compound class: Peptide or derivative

Comment: Efineptakin alfa is a long-acting immunoglobulin (Ig) fusion protein composed of recombinant human IL-7 fused to a hybrid Fc (hyFc) region of a human antibody. It comprises two disulphide bond-linked peptide chains. Efineptakin alfa has hematopoietic and immunopotentiating activities. In the oncology setting IL-7 enhances T-cell-mediated anti-tumour immune responses. Efineptakin alfa is being developed by Genexine (in-licensed to I-MAB Biopharma) and NeoImmuneTech. The peptide sequence of efineptakin alfa is claimed in Genexine's patent WO2016200219A1 as sequence 24 and would appear to be referred to as MGM-IL-7-hyFc therein [3].

Bioactivity Comments
The biological activity of MGM-IL-7-hyFc is ≥ than that of the international standard human IL-7 in murine immature 2E8 B lymphocytes in vitro [3]. Affinity for the IL-7 receptor is not provided.

Bioactivity Comments

The biological activity of MGM-IL-7-hyFc is ≥ than that of the international standard human IL-7 in murine immature 2E8 B lymphocytes in vitro [3]. Affinity for the IL-7 receptor is not provided.